Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 347

1.

Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC.

Gresele P, Orsini S, Noris P, Falcinelli E, Christine Alessi M, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontana P, Guglielmini G, Pecci A; BAT-VAL study investigators.

J Thromb Haemost. 2019 Nov 21. doi: 10.1111/jth.14683. [Epub ahead of print]

PMID:
31750621
2.

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.

Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW.

Blood Adv. 2019 Nov 12;3(21):3241-3247. doi: 10.1182/bloodadvances.2019000811.

3.

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, Pugliese FR, Lubrano R, Golato M, Tripodi A, Rocino A, Santagostino E; ad hoc Working Group.

Blood Transfus. 2019 Oct 18:1-8. doi: 10.2450/2019.0186-19. [Epub ahead of print]

4.

Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies.

Lunghi B, Lecchi A, Santacroce R, Scavone M, Paniccia R, Artoni A, Gachet C, Castaman G, Margaglione M, Bernardi F, Cattaneo M.

Haematologica. 2019 Oct 24. pii: haematol.2019.232850. doi: 10.3324/haematol.2019.232850. [Epub ahead of print]

5.

Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.

Castaman G, Borchiellini A, Santagostino E, Tagariello G, Serban M, Uscatescu M, Truica C, Farrugia A, Morfini M.

Haemophilia. 2019 Nov;25(6):e364-e367. doi: 10.1111/hae.13828. Epub 2019 Sep 11. No abstract available.

PMID:
31509326
6.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

PMID:
31444162
7.

Hemophilia A and B: molecular and clinical similarities and differences.

Castaman G, Matino D.

Haematologica. 2019 Sep;104(9):1702-1709. doi: 10.3324/haematol.2019.221093. Epub 2019 Aug 8. No abstract available.

8.

Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders.

Castaman G, Giacomelli SH, Biasoli C, Contino L, Radossi P.

Eur J Haematol. 2019 Oct;103(4):379-384. doi: 10.1111/ejh.13296. Epub 2019 Aug 1.

PMID:
31314131
9.

The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study.

Tosetto A, Testa S, Palareti G, Paoletti O, Nichele I, Catalano F, Morandini R, Di Paolo M, Tala M, Esteban P, Cora' F, Mannino S, Maroni A, Sessa M, Castaman G.

Intern Emerg Med. 2019 Nov;14(8):1307-1315. doi: 10.1007/s11739-019-02148-7. Epub 2019 Jul 15.

PMID:
31309520
10.

TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A.

Manetti M, Linari S, Romano E, Rosa I, Carulli C, Innocenti M, Matucci-Cerinic M, Ibba-Manneschi L, Castaman G, Melchiorre D.

J Clin Med. 2019 Jun 28;8(7). pii: E939. doi: 10.3390/jcm8070939.

11.

Pregnancy and delivery in women with von Willebrand disease.

Castaman G, James PD.

Eur J Haematol. 2019 Aug;103(2):73-79. doi: 10.1111/ejh.13250. Epub 2019 May 31. Review.

PMID:
31107984
12.

Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.

Lunghi B, Bernardi F, Martinelli N, Frusconi S, Branchini A, Linari S, Marchetti G, Castaman G, Morfini M.

J Thromb Haemost. 2019 Aug;17(8):1288-1296. doi: 10.1111/jth.14473. Epub 2019 May 29.

PMID:
31055871
13.

Current and emerging biologics for the treatment of hemophilia.

Castaman G, Linari S.

Expert Opin Biol Ther. 2019 Aug;19(8):801-810. doi: 10.1080/14712598.2019.1614163. Epub 2019 May 9.

PMID:
31039049
14.

Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) project.

Santagostino E, Riva A, Cesaro S, Esposito S, Matino D, Mazzucchelli RI, Molinari AC, Mura R, Notarangelo LD, Tagliaferri A, Di Minno G, Clerici M; the HEVA Study Group.

Haemophilia. 2019 Jul;25(4):656-667. doi: 10.1111/hae.13756. Epub 2019 Apr 16.

15.

Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.

Gill JC, Roberts J, Li Y, Castaman G.

Haemophilia. 2019 May;25(3):e219-e222. doi: 10.1111/hae.13735. Epub 2019 Mar 13. No abstract available.

PMID:
30866086
16.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Sep;17(5):391-398. doi: 10.2450/2019.0183-18. Epub 2019 Feb 4.

17.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.

Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders.

J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. No abstract available.

18.

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1), De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G.

Blood Transfus. 2019 May;17(3):171-180. doi: 10.2450/2018.0143-18. Epub 2018 Oct 24.

19.

XXV Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).

Ageno W, Falanga A, Castaman G.

Blood Transfus. 2018 Nov 7;16(Supplement no. 4):s415-s562. doi: 10.2450/2018.S4. [Epub ahead of print] No abstract available.

20.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

Supplemental Content

Loading ...
Support Center